Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency and generate cost savings for oncology practices without affecting efficacy or safety.
Operationalizing Bispecific Antibodies for Hematological Cancers: Insights From ASH 2025
While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with operational efficiency and cost savings serving as added benefits rather than decision drivers.
Advertisement
Advertisement
Trending on AJMC
1
5 Key Health Care Changes During Trump’s First Year Back in Office
2
J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort
3
Maternal Morbidity Increased in States Enacting TRAP Laws
4
Zanidatamab Shows Breakthrough Survival Gains in Metastatic Gastroesophageal Cancer: Elena Elimova, MD
5
